Tatva Chintan Pharma Chem Limited has informed the Exchange about Transcript
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan reported Q2 FY26 operating revenue of INR1,235 million, up 48% year-on-year and 6% sequentially, with EBITDA jumping 298% YoY to INR222 million. The Structure Directing Agents (SDA) segment led the recovery, growing 119% YoY to INR593 million, driven by Euro 7 emission norms and restocking in non-China markets. Management guided EBITDA margins to reach 20-22% over the next two quarters as plant occupancy improves, noting current SDA plant utilization is only around 50%. A new plant block in Jolva will commence commercial production from January 2026, which is expected to ease bottlenecks in pharma and agro intermediates. The electrolyte salts segment is targeted to reach INR15 crore in revenue, with the semiconductor chemicals business expected to deliver plant-scale commercial batches in Q4 FY26 and full commercialization by 2027-2028.
Strong quarterly results and clear margin recovery guidance signal a turnaround story; however, significant execution risk remains around new product commercialization timelines and capacity ramp-up. Shareholders should watch for the January 2026 plant commissioning and any updates on semiconductor customer audits as key near-term catalysts.